Proactive Investors
21 Sept 2026, 00:03 UTC · 8w ago
Orthocell records first Remplir sales in US$84 million Thai nerve repair market
Impact · against what's priced in
The first commercial sales in Thailand provide a modest new revenue stream, but the immediate financial impact is limited. The primary value driver remains the upcoming EU/UK regulatory decision expected in H2 2026.
- OCC+0.20
No priced-in read yet
- In context
The recording of first commercial sales in Thailand's US$84 million nerve repair market opens a new geographic revenue stream, although management expects near-term volumes to remain modest.
Read from the article alone

Search tags




